Matching articles for "Opsynvi"
Issue 1737 · September 15, 2025 Free
In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists

The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics),…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):152 doi:10.58347/tml.2025.1737e
The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics), macitentan ( Opsumit , and generics; Opsynvi) , and aprocitentan (Tryvio) , and the endothelin receptor antagonist and angiotensin II receptor antagonist sparsentan (Filspari) that was initially implemented because of a possible risk of embryofetal toxicity.
Issue 1702 · May 13, 2024
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical…

Med Lett Drugs Ther. 2024 May 13; 66(1702):73-5 doi:10.58347/tml.2024.1702a
The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).